 Kura Oncology, Inc. KURA, a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported first quarter 2020 financial results and provided a corporate update. We recently completed a strategic review of our portfolio with the goal of prioritizing programs that have the highest potential to create value, said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. 